More than half of patients with newly diagnosed large B-cell lymphoma (LBCL) may reduce or remove chemotherapy with a targeted therapy–first strategy, according to data from the primary analysis of the Smart Stop trial (NCT04978584) presented…
“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL
